Discussions With FDA Provide Guidance For Phase IIb Clinical Trial Design For DMT-assisted Therapy For Major Depressive Disorder
LONDON, Nov. 15, 2021 -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a neuropharmaceutical company focused on psychedelic-assisted therapies, today confirms, following positive discussions with the U.S. Food and Drug Administration (the “FDA”), that preparations are now underway for the U.S. component of its Phase IIb clinical trial for its lead candidate, SPL026, a N,N-dimethyltryptamine (“DMT”) assisted therapy for the treatment of major d
First patient dosed in Phase IIA DMT-assisted therapy clinical trial
LONDON, Sept. 21, 2021 /PRNewswire/ -- Small Pharma Inc. (TSXV: DMT) (the "Company" or "Small Pharma"), a neuropharmaceutical company focused on psychedelic-assisted therapies, today announced both the successful completion of the Phase I part of the combined Phase I/IIa clinical trial and the initiation of the Phase IIa part in combination with psychotherapy of its lead candidate, SPL026, for the treatment of Major Depressive Disorder ("MDD").
Small Pharma successfully completes Phase I Clinical Trial of DMT in Combination with Supportive Psychotherapy.
LONDON, Sept. 21, 2021 /PRNewswire/ -- Small Pharma Inc. (TSXV: DMT) (the "Company" or "Small Pharma"), a neuropharmaceutical company focused on psychedelic-assisted therapies, today announced both the successful completion of the Phase I part of the combined Phase I/IIa clinical trial and the initiation of the Phase IIa part in combination with psychotherapy of its lead candidate, SPL026, for the treatment of Major Depressive Disorder ("MDD").
Psychedelic solution for depression: British drug firm starts clinical trials of new treatment that sends patients on a hallucinogenic trip
Small Pharma is carrying out clinical trials of a drug based on chemical DMT It is a psychedelic found in plants and animals that produces hallucinations The clinical trials aim to see if it can work with therapy to treat severe depression Assuming it works it could be on the market within the next six years, […]
Small Pharma Inc. expands Phase I/IIa clinical trial with additional study site
LONDON, June 1, 2021 -- Small Pharma Inc. (TSXV: DMT) (the "Company" or "Small Pharma"), a neuropharmaceutical company focused on psychedelic-assisted therapies, today announces the expansion of its Phase I/IIa clinical trial for its lead product, SPL026, a N,N-dimethyltryptamine ("DMT") based treatment for major depressive disorder ("MDD").
Powerful hallucinogenic drug used in shamanic rituals is being trialled in the UK as a cure for depression
The hallucinogenic drug DMT is being trialled on British depression patients It is hoped it will help bring relief to those who don’t respond to normal pills Evidence suggests that DMT in combination with talking therapy can help A powerful hallucinogenic drug that has been used in shamanic rituals is being trialled by a British […]
Psychedelic therapy could ‘reset’ depressed brain
A powerful hallucinogenic drug known for its part in shamanic rituals is being trialled as a potential cure for depression for the first time. Participants will be given the drug DMT, followed by talking therapy. It is hoped this could offer an alternative for the significant number of people who don’t respond to conventional pills […]
‘First Ever’ DMT Trials to Take Place in the UK
Small Pharma, a pharmaceutical company that focuses on depression and mental health, has secured approval to begin clinical trials with DMT, the psychedelic drug (nicknamed “the spirit molecule”) that is often considered the world’s most potent. Ethnobotanist Terence McKenna, for instance, described it as “the most powerful hallucinogen known to man and science”. While psychiatrists in the […]